Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;112:587-591
Published online before print July 18, 2005, doi: 10.1161/CIRCULATIONAHA.104.509778
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
112/4/587    most recent
CIRCULATIONAHA.104.509778v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakao, A.
Right arrow Articles by Kanno, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakao, A.
Right arrow Articles by Kanno, S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Vascular Diseases
Related Collections
Right arrow Restenosis
Right arrow Animal models of human disease
Right arrow Apoptosis
Right arrow Smooth muscle proliferation and differentiation
Right arrow CV surgery: coronary artery disease
Right arrow Other Vascular biology

(Circulation. 2005;112:587-591.)
© 2005 American Heart Association, Inc.


Vascular Medicine

Biliverdin Administration Prevents the Formation of Intimal Hyperplasia Induced by Vascular Injury

Atsunori Nakao, MD; Noriko Murase, MD; Chien Ho, PhD; Hideyoshi Toyokawa, MD; Timothy R. Billiar, MD; Shinichi Kanno, MD

From the Thomas E. Starzl Transplantation Institute (A.N., N.M., H.T.) and Department of Surgery (T.R.B., S.K.), University of Pittsburgh, Pittsburgh, Pa, and the NMR Center, Carnegie Mellon University (C.H.), Pittsburgh, Pa.

Correspondence to Shinichi Kanno, MD, Department of Surgery, University of Pittsburgh, School of Medicine, W1554, Biomedical Science Tower, 200 Lothrop St, Pittsburgh, PA 15213. E-mail shk34{at}pitt.edu

Received September 27, 2004; revision received March 29, 2005; accepted April 12, 2005.

Background— Autologous vein grafts and balloon angioplasty are still commonly used for arterial reconstructive procedures. Their success is limited by the development of intimal hyperplasia (IH). Biliverdin (BVD), one of the by-products of heme degradation, has been shown to have potent antioxidant and antiinflammatory effects. We hypothesized that BVD administration would protect vascular tissue against vascular injury.

Methods and Results— The effects of BVD administration against IH after vascular injury were analyzed in an arterialized vein graft model and a balloon injury model in rats. BVD treatment significantly suppressed the development of IH in both models compared with those without BVD. The mechanisms by which BVD treatment inhibits IH development might include decreasing c-Jun NH2 terminal kinase activation and preventing apoptosis of endothelial cells. BVD also suppressed vascular smooth muscle cell migration in vitro.

Conclusions— BVD administration prevented IH associated with arterialized vein graft vasculopathy or balloon angioplasty-induced vessel injury. These results suggest that a treatment regimen with exogenous BVD administration could provide an effective therapeutic adjunct to facilitate transfer of experimental treatments for vascular injury to the clinic.


Key Words: angioplasty • antioxidants • apoptosis • reperfusion • restenosis




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
R. C.M. Siow and A. T. Churchman
Adventitial growth factor signalling and vascular remodelling: Potential of perivascular gene transfer from the outside-in
Cardiovasc Res, September 1, 2007; 75(4): 659 - 668.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
N. Hill-Kapturczak and A. Agarwal
Haem oxygenase-1--a culprit in vascular and renal damage?
Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1495 - 1499.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. Kronke, A. Kadl, E. Ikonomu, S. Bluml, A. Furnkranz, I. J. Sarembock, V. N. Bochkov, M. Exner, B. R. Binder, and N. Leitinger
Expression of Heme Oxygenase-1 in Human Vascular Cells Is Regulated by Peroxisome Proliferator-Activated Receptors
Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1276 - 1282.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A.-L. Levonen, M. Inkala, T. Heikura, S. Jauhiainen, H.-K. Jyrkkanen, E. Kansanen, K. Maatta, E. Romppanen, P. Turunen, J. Rutanen, et al.
Nrf2 Gene Transfer Induces Antioxidant Enzymes and Suppresses Smooth Muscle Cell Growth In Vitro and Reduces Oxidative Stress in Rabbit Aorta In Vivo
Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 741 - 747.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Stocker and M. A. Perrella
Heme Oxygenase-1: A Novel Drug Target for Atherosclerotic Diseases?
Circulation, November 14, 2006; 114(20): 2178 - 2189.
[Full Text] [PDF]


Home page
Physiol. Rev.Home page
S. W. Ryter, J. Alam, and A. M. K. Choi
Heme Oxygenase-1/Carbon Monoxide: From Basic Science to Therapeutic Applications
Physiol Rev, April 1, 2006; 86(2): 583 - 650.
[Abstract] [Full Text] [PDF]